Yu-Ting Chen
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,290 of the $1,788 with a category attached, or 72.2%. Alnylam Pharmaceuticals Inc. accounts for 79.1% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2023 at $1,353 and has fallen 87.1% since, to $175 in 2025.
Across 12 payments — averaging $148.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$1K
- Neurelis, Inc.$98
- TG Therapeutics, Inc.$75
- Johnson & Johnson$61
- Biogen$47
- Tanabe Pharma America, Inc.$24
- plus $70 from 4 others
What the payments were for
- Consulting fees$1,29072%
- Food & beverage$49828%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 2 | $1,413 |
| Neurelis, Inc. | 1 | $98 |
| TG Therapeutics, Inc. | 2 | $75 |
| Johnson & Johnson | 1 | $61 |
| Biogen | 1 | $47 |
| Tanabe Pharma America, Inc. | 1 | $24 |
| Verona Pharma, Inc. | 1 | $21 |
| AstraZeneca | 1 | $18 |
| Boston Scientific | 1 | $16 |
| UCB, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMVUTTRA$123
How this compares
$1,788 in reported general payments places this provider in the 60th percentile of 105 neurology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Radicava OrsEdaravone | 22 | $312,958 |
| Riluzole | 11 | $15,023 |
| LyricaPregabalin | 20 | $11,004 |
| Gabapentin | 65 | $6,224 |
| Mycophenolate Mofetil | 17 | $1,266 |
| Pyridostigmine Bromide | 16 | $839 |
| Azathioprine | 14 | $486 |
| Prednisone | 44 | $350 |
| Oxcarbazepine | 11 | $259 |
| Pantoprazole Sodium | 27 | $210 |
Paid to pharmacies, not to this prescriber.
Other neurology in Omaha
- Chad WhyteOmaha$647K
- Scott GoodmanOmaha$377K
- Rana ZabadOmaha$276K
- Deepak MadhavanOmaha$189K
- Pamela SantamariaOmaha$90K
- Peter SohOmaha$60K
- Kiel WoodwardOmaha$32K
- Pierre FayadOmaha$24K
- Jonathan MoravekOmaha$19K
- Erin SmithOmaha$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.